BioNTech Investor Day Presentation Deck

2 Variant-adapted vaccines I Reactogenicity profile of variant vaccines overall similar to prototype BNT162b2 vaccine Participants aged 18-55 years Monovalent Omicron-modified vaccine (30 µg) showed a similar local reaction and systemic event profile as the prototype vaccine (30 µg) Internal data. Participants aged >55 years Monovalent and bivalent Omicron-modified vaccines (30 µg) showed a similar local reaction and systemic event profile as the prototype vaccine NUA 60 µg dose level: Mild to moderate injection site pain, fatigue and muscle pain were more common compared to 30 µg Pandemic prep. CAR Pfizer BIONTECH 71

View entire presentation